CBL-514 timeline
Current statusSUPREME-01 remains recruiting after first dosing. Sponsor announces SUPREME-02 enrollment, although the October 20 registry still says not yet recruiting. No Phase 3 result is available. Small exploratory visceral-fat findings remain separate; CBL-514 has no marketing approval or commercial availability. Separately, a small Chinese PK/safety trial receives sponsor-reported clearance; it is not another Phase 3 outcome.
12 / 14
Occurred6 Nov 2026sponsor development/timing disclosure
CBL-514 gains sponsor-reported China trial clearance
Caliway reports CBL-0102 clearance in China: approximately 30 healthy participants, single-dose pharmacokinetics and safety. December enrollment and Q2 2027 completion are forecasts, separate from SUPREME Phase 3 results.
Step 12 of 14
Evidence limitations. Abdominal subcutaneous fat, visceral fat and body weight are different endpoints. The published Phase 2b study had substantial attrition and unblinded clinician ratings; trial clearance is not marketing approval.
Dated events are ordered; spacing is schematic. Undated steps have no fixed timing. · Checked Nov 6, 2026. Read the topic research